

Incidence

Table 2 Incidence of ILD in gefitinib-treated patients (Forsythe and Faulkner, 2003b)

Gefitinib-treated patients	Incidence of ILD (death), %
Globally ($n = \sim 92\,750$)	0.99 (0.36)
Japan marketed use ($n = \sim 39\,600$)	<u>1.86 (0.69)</u>
Outside Japan ($n = \sim 53\,150$)	<u>0.34 (0.11)</u>
US EAP ($n = \sim 24\,200$)	0.39 (0.08)
Rest of world EAP ($n = \sim 15\,000$)	0.38 (0.21)

EAP = expanded access programme; ILD = interstitial lung disease.


Risk factor of ILD

Table 2. Risk Factors for Interstitial Lung Disease Identified by Multivariate Logistic Regression Analysis (n = 1,586*)

Variable	Odds Ratio	95% CI	<i>P</i>
Male	3.10	1.15 to 8.36	.025
Positive smoking history	4.79	1.69 to 13.54	.003
Coincidence of IP	2.89	1.06 to 7.84	.038
BSA of < 1.5 m ²	1.67	0.98 to 2.83	.059


Abbreviations: IP, interstitial pneumonia; BSA, body-surface area.

*Including 66 patients with gefitinib-induced interstitial lung disease.



AJRCCM 2008; 177:1348-57

Asia Pac J Clin Oncol 2007;3:66-78.



Our experience in NYMUH


- Name: 徐XX; 72 y/o female
- Adenocarcinoma of lung, RLL, with malignant pleural effusion, diagnosed 97/11
- s/p Navelbine x 7, shifted to Iressa (98/5/22)

➔ Fever, SOB, non productive cough (5/25)

2009



Chest CT scan




2009/5/29

Iressa since 98/5/22

2009/4/29

Incidence of ILD during Gefitinib treatment in Taiwan: 0.17 % ????





4 (5.8%) of 69 patients developed ILD during gefitinib treatment


We consecutively recruited 1080 patients treated with gefitinib

	Patients (%)		
	NTUH	FEMH	NYMUH
Gefitinib use	969	85	26
ILD	21	2	2
Incidence (%)	2.1	2.3	7.7

From April 2004 to May 2009, 25 (2.3%) of 1080 patients developed ILD during gefitinib treatment



ILD is a serious adverse effect





**In-hospital
mortality=54.2 %**


**1 year survival after
ILD onset=21.8%**

Cox regression analysis in-hospital mortality

Variables	Hazard ratio	95% C.I.	P value
<u><i>Gefitinib non-responder</i></u>	10.55	1.20 – 92.40	0.03
Non 1 st -line use	4.30	0.79 – 23.58	0.09
SpO ₂ <80 %	0.33	0.07 – 1.60	0.17
Mechanical ventilation	3.02	0.65 – 9.41	0.13

Prediction by specific EGFR mutations





AJRCCM 2008; 177:1348-57

Table 2 Frequency of radiological patterns of ILD induced by gefitinib and mortality

Radiological pattern	Frequency		Mortality
	Chest radiography	CT	
A	29 (43.8%)	24 (47.1%)	9 (31.0%)
B	7 (10.0%)	7 (13.7%)	2 (28.6%)
C	3 (4.3%)	1 (2.0%)	0 (0.0%)
D	20 (28.6%)	12 (23.5%)	15 (75.0%)
Others	11 (15.7%)	7 (13.7%)	5 (45.5%)
Total	70	51	31 (44.3%)

- A: Non specific area with ground glass attenuation
- B: A multifocal area of airspace consolidations
- C: Patchy distribution of ground glass attenuation accompanied by interlobar septal thickening
- D: Extensive bilateral ground glass attenuation or airspace consolidation with traction bronchiectasis



(a)



(b)

pattern A

Fig. 1 A 60-year-old male with stage IV non-small cell lung cancer who had been treated with platinum-based chemotherapy developed mild dyspnea on day 10 after administration of gefitinib. The chest radiography reveals a mass opacity in the right hilum and diffuse ground-glass density over the entire lung field against a background of emphysema and fibrosis (a). The CT scan shows nonspecific areas with ground-glass attenuation throughout the lung parenchyma (b).



(a)



(b)

pattern B

Fig. 2 A 70-year-old male with stage IIIB adenocarcinoma who had been treated with platinum-based chemotherapy was started on gefitinib, and developed a severe cough and mild dyspnea on day 30 of gefitinib therapy. The chest radiography shows areas of consolidation on the upper and lower field of the right lung (a), and multifocal areas of airspace consolidation are seen on the thin-section CT scan (b).



(a)



(b)


pattern D

Fig. 3 A 62-year-old male who had undergone right upper lobectomy complained of the acute onset of dyspnea on day 5 after the start of gefitinib therapy. The antero-posterior chest radiography shows diffuse ground-glass densities in the lung parenchyma (a). The CT scan shows extensive bilateral ground-glass attenuation and airspace consolidations with traction bronchiectasis (b). The patient died 10 days after the onset of ILD despite treatment by steroid pulse therapy.

Our Experience in Radiological Patterns of ILD Induced by Gefitinib and Mortality

Radiological Pattern	Chest X-ray	CT	Mortality
A	8 (32.0%)	8 (34.8%)	3 (34.8 %)
B	3 (12.0%)	3 (13.0%)	0 (0.0%)
C	6 (24.0%)	5 (21.7%)	2 (33.3%)
D	8 (32.0%)	7 (30.4%)	8 (100%)
Total	25	23	13 (56.5%)

Imaging patterns and prognosis of patients with gefitinib-related ILD




Treatments

- There is no specific treatment, but supportive therapy including
 - DC iressa
 - Oxygen
 - Corticosteroids
 - (Rigimen)
 - MTP IV (1 g/day) x 3 days
 - » (Respirology, 2006 11, 113–116) case report
 - MTP IV (2mg/kg/day~1 g/day) -> Prednisolone PO (20-30 mg/day)
 - » Respiratory Medicine (2006) 100, 698–704
 - steroid less effective in AIP
 - Assisted ventilation is indicated

Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review

Li-Chiao Kuo · Po-Chou Lin · Ko-Fan Wang ·
Mei-Kang Yuan · Shih-Chieh Chang



Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia

Shih-Chieh Chang, Cheng-Yu Chang,† Chiung-Yu Chen,‡ and Chong-Jen Yu‡*

